Drug Profile
Research programme: antisense drug therapies - Ionis/Xenon
Alternative Names: XEN 701Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Xenon Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Hepcidin inhibitors; HFE2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Anaemia in Canada (unspecified route)
- 22 Feb 2023 Discontinued for Anaemia in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Anaemia in Canada